Endo Announces Agreement with Slayback Pharma to Distribute Prevduo™ (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Product in the U.S.

DUBLIN, April 26, 2023 /PRNewswire/ — Endo International plc (OTC: ENDPQ) announced today that its subsidiaries Endo Ventures Limited and Par Pharmaceutical, Inc. (collectively “Endo”) have executed an agreement with Slayback Pharma LLC to distribute Slayback’s Prevduo™ (neostigmine…